

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FOURTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM JANUARY 1, 2020 THROUGH JANUARY 31, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	January 1, 2020 through January 31, 2020
Monthly Fees Incurred:	\$774,662.00

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$11,530.84

Total Fees and Expenses Due: \$786,192.84

This is a: X monthly _____ interim _____ final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$623,033.20	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$662,060.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$641,629.20	\$2,284.19

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from January 1, 2020 through and including January 31, 2020 (the “**Fourth Fee Period**”) amount to:

Professional Fees	\$774,662.00
Expenses	<u>11,530.84</u>
TOTAL	<u>\$786,192.84</u>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$619,729.60
Expenses at 100%	<u>11,530.84</u>
TOTAL	<u>\$631,260.44</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fourth Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fourth Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Fourth Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. A summary of expenses incurred during the Fourth Fee Period is set forth on the schedule annexed hereto as **Exhibit “D.”**

7. Detailed breakdown of the expenses incurred during the Fourth Fee Period is set forth on the schedule annexed hereto as **Exhibit “E.”**
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fourth Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than March 26, 2020 (the “Objection Deadline”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “Objection”).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
March 12, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020**

Professional	Position	Specialty	Billing Rate^{1,2}	Total Hours	Total Fees
Bradley, Adam	Sr Managing Dir	International Healthcare	\$ 1,160	13.0	\$ 15,080.00
Diaz, Matthew	Sr Managing Dir	Restructuring	1,085	137.0	148,645.00
Eisenband, Michael	Sr Managing Dir	Restructuring	1,295	1.5	1,942.50
Greenblatt, Matthew	Sr Managing Dir	Forensics	985	4.3	4,235.50
Joffe, Steven	Sr Managing Dir	Tax	1,125	17.6	19,800.00
Simms, Steven	Sr Managing Dir	Restructuring	1,295	5.3	6,863.50
Turner, Richard	Sr Managing Dir	Tax	1,085	2.2	2,387.00
Broadhead, Gary	Managing Dir	International Healthcare	1,000	83.0	83,000.00
Kyviakidis, Peter	Managing Dir	Forensics	765	0.8	612.00
Knechtel, Karl	Senior Director	Restructuring	845	56.1	47,404.50
Shah, Jayshree	Senior Director	International Healthcare	930	23.0	21,390.00
Vohra, Paul	Senior Director	International Healthcare	930	2.0	1,860.00
Bromberg, Brian	Director	Restructuring	815	221.4	180,441.00
Suric, Emil	Director	Healthcare	735	39.6	29,106.00
Tsongidis, Theodoros	Sr Consultant	International Healthcare	735	98.1	72,103.50
Kim, Ye Darm	Consultant	Restructuring	455	85.6	38,948.00
Kurtz, Emma	Consultant	Restructuring	415	67.1	27,846.50
Limoges Friend, Alexander	Consultant	International Healthcare	625	115.7	72,312.50
Tirabassi, Kathryn	Consultant	Restructuring	455	30.1	13,695.50
Hellmund-Mora, Marili	Project Asst	Restructuring	280	1.0	280.00
SUBTOTAL					787,953.00
Less: 50% Travel Time					(13,291.00)
GRAND TOTAL				1,004.4	\$ 774,662.00

1. Billing rates reflect an ordinary course rate increase effective 1/1/2020.

2. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	18.0	\$ 11,689.00
2	Cash & Liquidity Analysis	4.2	2,379.00
5	Real Estate Issues	3.9	3,655.50
7	Analysis of Domestic Business Plan	87.5	70,107.50
10	Analysis of Tax Issues	46.7	45,998.50
18	Review of Historical Transactions	22.0	21,525.00
19	Case Management	6.7	6,876.50
21	General Mtgs with Counsel and/or Ad Hoc Committee	15.2	14,243.00
24	Preparation of Fee Application	20.9	10,909.50
25	Travel Time	29.8	26,582.00
28	Review of IAC Business Plan	749.5	573,987.50
SUBTOTAL		1,004.4	787,953.00
Less: 50% Travel Time			(13,291.00)
GRAND TOTAL^{1,2}		1,004.4	\$ 774,662.00

1. Billing rates reflect an ordinary course rate increase effective 1/1/2020.

2. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
1	1/2/2020	Kurtz, Emma	0.3	Prepare summary re: key docket filings and media coverage for distribution to team.
1	1/2/2020	Tirabassi, Kathryn	1.3	Prepare updated weekly flash report.
1	1/3/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/6/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/8/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/9/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/13/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/14/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/17/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/21/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/21/2020	Tirabassi, Kathryn	0.7	Incorporate updates to flash report.
1	1/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/22/2020	Tirabassi, Kathryn	0.6	Incorporate updates to flash report.
1	1/23/2020	Diaz, Matthew	1.2	Review the November operating results.
1	1/23/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/27/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/28/2020	Knechtel, Karl	2.3	Review the updated flash report.
1	1/28/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/29/2020	Knechtel, Karl	3.1	Prepare detailed comments re: updated flash report.
1	1/29/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/30/2020	Knechtel, Karl	0.9	Review the updated flash report.
1	1/30/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/31/2020	Knechtel, Karl	1.4	Prepare comments re: updated flash report.
1	1/31/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			18.0	

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
2	1/15/2020	Tirabassi, Kathryn	0.6	Prepare analysis re: updated cash flows.
2	1/16/2020	Tirabassi, Kathryn	2.4	Prepare analysis re: updated cash flows.
2	1/22/2020	Knechtel, Karl	1.2	Review updated cash activity presentation.
2 Total			4.2	
5	1/21/2020	Knechtel, Karl	0.6	Participate in discussion with the Debtors re: lease proposal.
5	1/29/2020	Knechtel, Karl	0.3	Participate on call with the Debtors re: lease proposal.
5	1/30/2020	Knechtel, Karl	0.6	Review lease extension questions and respond to counsel.
5	1/31/2020	Diaz, Matthew	0.6	Review the updated Purdue real estate lease.
5	1/31/2020	Diaz, Matthew	0.9	Participate on call with Debtor and CBRE re: proposed lease agreement.
5	1/31/2020	Knechtel, Karl	0.9	Participate on call with Debtor and CBRE re: proposed lease agreement.
5 Total			3.9	
7	1/2/2020	Knechtel, Karl	1.3	Review public health initiatives and next steps.
7	1/2/2020	Knechtel, Karl	1.9	Review proposed manufacturing agreement.
7	1/2/2020	Suric, Emil	2.1	Review materials re: potential transactions.
7	1/2/2020	Tirabassi, Kathryn	1.8	Prepare analysis re: potential transactions.
7	1/3/2020	Diaz, Matthew	0.7	Review summary re: potential transactions.
7	1/3/2020	Knechtel, Karl	1.1	Participate on call with Alix, the Debtors, Province, and Jefferies re: potential transactions.
7	1/3/2020	Knechtel, Karl	1.8	Review summary re: potential transactions.
7	1/3/2020	Suric, Emil	2.7	Prepare analysis re: potential transactions.
7	1/3/2020	Suric, Emil	3.3	Prepare analysis re: public health initiatives.
7	1/3/2020	Tirabassi, Kathryn	0.7	Review materials in preparation for potential transactions call.
7	1/3/2020	Tirabassi, Kathryn	1.1	Participate on call with Alix, the Debtors, Province, and Jefferies re: potential transactions.
7	1/6/2020	Diaz, Matthew	0.6	Review the Debtors' public health initiatives and related next steps.
7	1/6/2020	Knechtel, Karl	1.8	Prepare analysis re: public health initiatives.
7	1/6/2020	Tirabassi, Kathryn	0.7	Review public health initiatives.
7	1/7/2020	Knechtel, Karl	2.4	Prepare comments re: potential transactions analysis.
7	1/8/2020	Diaz, Matthew	0.8	Review the slides for the Committee re: the business update.
7	1/8/2020	Diaz, Matthew	1.1	Review the proposed transactions.
7	1/8/2020	Knechtel, Karl	0.9	Participate on call with the Debtors re: business plan.
7	1/8/2020	Tirabassi, Kathryn	0.9	Participate on call with the Debtors re: business plan.
7	1/8/2020	Tirabassi, Kathryn	1.9	Prepare summary slide re: potential transactions.
7	1/9/2020	Knechtel, Karl	1.3	Review summary re: potential transactions.
7	1/13/2020	Knechtel, Karl	0.4	Review updated public health initiative analysis.
7	1/16/2020	Suric, Emil	2.9	Prepare analysis re: public health initiatives.
7	1/17/2020	Suric, Emil	1.4	Continue to prepare further analysis re: public health initiatives.
7	1/17/2020	Suric, Emil	2.4	Continue to prepare further analysis re: public health initiatives.
7	1/17/2020	Suric, Emil	2.9	Prepare further analysis re: public health initiatives.
7	1/21/2020	Diaz, Matthew	1.6	Conduct a detailed review of the public health initiative analysis.
7	1/21/2020	Knechtel, Karl	2.1	Review public health initiatives.
7	1/21/2020	Suric, Emil	2.2	Prepare further analysis re: public health initiatives.
7	1/21/2020	Suric, Emil	2.8	Prepare summary re: public health initiatives.
7	1/22/2020	Diaz, Matthew	0.7	Review the public health initiative analysis.
7	1/22/2020	Knechtel, Karl	3.2	Incorporate updates to summary re: public health initiatives.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
7	1/22/2020	Suric, Emil	2.4	Continue to conduct research re: public health initiatives.
7	1/22/2020	Suric, Emil	2.6	Conduct research re: public health initiatives.
7	1/23/2020	Diaz, Matthew	1.2	Review the updated public health initiative analysis.
7	1/23/2020	Suric, Emil	2.7	Prepare summary re: public health initiatives.
7	1/24/2020	Suric, Emil	1.3	Review management's responses to questions re: public health initiatives.
7	1/27/2020	Diaz, Matthew	0.6	Review the updated PHI analysis.
7	1/27/2020	Knechtel, Karl	0.8	Participate on call with UCC re: public health initiatives.
7	1/27/2020	Knechtel, Karl	1.4	Review public health initiative questions in advance of call.
7	1/27/2020	Suric, Emil	1.6	Incorporate updates to analysis re: public health initiatives.
7	1/28/2020	Suric, Emil	1.1	Incorporate updates to summary re: public health initiatives.
7	1/29/2020	Diaz, Matthew	1.5	Review the updated public health initiatives analysis.
7	1/29/2020	Knechtel, Karl	2.2	Update public health initiative questions.
7	1/29/2020	Suric, Emil	0.4	Incorporate updates to summary re: public health initiatives.
7	1/29/2020	Suric, Emil	1.6	Incorporate updates to analysis re: public health initiatives.
7	1/30/2020	Diaz, Matthew	1.2	Review the updated public health initiative analysis.
7	1/30/2020	Diaz, Matthew	1.5	Review the updated public health initiative presentation to the Committee.
7	1/30/2020	Knechtel, Karl	1.0	Participate in meeting with Jefferies, PJT and others to discuss public health initiatives analysis.
7	1/30/2020	Knechtel, Karl	1.7	Review research re: public health initiatives.
7	1/30/2020	Suric, Emil	1.0	Participate in meeting with Jefferies, PJT and others to discuss public health initiatives analysis.
7	1/31/2020	Diaz, Matthew	0.6	Draft public health initiative update email to counsel.
7	1/31/2020	Diaz, Matthew	1.4	Review the updated public health initiative analysis.
7	1/31/2020	Knechtel, Karl	1.2	Participate in meeting with the Debtors re: public health initiatives.
7	1/31/2020	Knechtel, Karl	1.3	Prepare summary re: autoinjector.
7	1/31/2020	Suric, Emil	0.5	Review materials in preparation for meeting re: public health initiatives.
7	1/31/2020	Suric, Emil	1.2	Participate in meeting with the Debtors re: public health initiatives.
7 Total			87.5	
10	1/2/2020	Bromberg, Brian	1.1	Revise tax summary analysis.
10	1/2/2020	Joffe, Steven	1.3	Review tax summary.
10	1/3/2020	Bromberg, Brian	0.6	Review IAC tax analysis.
10	1/3/2020	Bromberg, Brian	2.4	Incorporate updates to tax summary.
10	1/3/2020	Diaz, Matthew	1.4	Review the updated tax analysis.
10	1/3/2020	Joffe, Steven	1.2	Review the updated tax summary.
10	1/6/2020	Bromberg, Brian	1.0	Review transfer pricing documents provided in dataroom.
10	1/6/2020	Diaz, Matthew	1.3	Conduct a detailed review of the updated tax summary.
10	1/6/2020	Joffe, Steven	1.1	Prepare comments re: updated tax analysis.
10	1/7/2020	Bromberg, Brian	1.3	Review tax value allocation.
10	1/7/2020	Bromberg, Brian	1.4	Incorporate updates to tax summary.
10	1/7/2020	Diaz, Matthew	1.3	Review the updated IAC tax summary.
10	1/7/2020	Joffe, Steven	3.1	Review the latest version of the IAC tax summary.
10	1/7/2020	Turner, Richard	2.2	Analyze transfer pricing documents.
10	1/8/2020	Bromberg, Brian	1.1	Incorporate further comments to tax summary.
10	1/8/2020	Joffe, Steven	0.3	Review updated tax analysis.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
10	1/9/2020	Bromberg, Brian	1.0	Participate on call with tax professionals re: updated tax analysis.
10	1/9/2020	Joffe, Steven	1.0	Review the updated IAC tax summary.
10	1/22/2020	Bromberg, Brian	1.0	Prepare summary re: tax analysis.
10	1/22/2020	Bromberg, Brian	1.1	Participate in a call with the Committee's professionals to discuss the IAC taxes.
10	1/22/2020	Diaz, Matthew	1.1	Participate in a call with the Committee's professionals to discuss the IAC taxes.
10	1/22/2020	Joffe, Steven	1.1	Participate in a call with the Committee's professionals to discuss the IAC taxes.
10	1/22/2020	Joffe, Steven	1.1	Review updated tax analysis.
10	1/23/2020	Bromberg, Brian	1.4	Prepare additional analysis re: tax.
10	1/23/2020	Bromberg, Brian	2.2	Incorporate comments to tax summary.
10	1/23/2020	Diaz, Matthew	0.9	Review the updated tax analysis.
10	1/23/2020	Joffe, Steven	1.4	Prepare comments re: updated tax analysis.
10	1/24/2020	Bromberg, Brian	0.7	Incorporate comments from the team to tax analysis.
10	1/27/2020	Bromberg, Brian	0.8	Incorporate comments to tax summary.
10	1/27/2020	Diaz, Matthew	0.4	Review the updated version of the tax summary.
10	1/27/2020	Joffe, Steven	0.5	Participate on call with counsel re: tax analysis.
10	1/28/2020	Bromberg, Brian	0.8	Incorporate further updates to IAC tax analysis.
10	1/28/2020	Diaz, Matthew	0.9	Review the updated IAC tax analysis.
10	1/28/2020	Joffe, Steven	2.3	Review the updated tax analysis.
10	1/29/2020	Bromberg, Brian	0.5	Participate on call with counsel re: tax analysis.
10	1/29/2020	Joffe, Steven	0.5	Participate on call with counsel re: tax analysis.
10	1/30/2020	Bromberg, Brian	1.3	Participate on call with counsel re: tax analysis.
10	1/30/2020	Diaz, Matthew	1.3	Participate on call with counsel re: tax analysis.
10	1/30/2020	Joffe, Steven	1.3	Participate on call with counsel re: tax analysis.
10 Total			46.7	
18	1/2/2020	Greenblatt, Matthew	3.2	Review next steps in connection with cash transfers report.
18	1/7/2020	Greenblatt, Matthew	0.8	Participate on call with Alix re: cash transfers analysis.
18	1/7/2020	Knechtel, Karl	0.8	Participate on call with Alix re: cash transfers analysis.
18	1/7/2020	Kyriakidis, Peter	0.8	Participate on call with Alix re: cash transfers analysis.
18	1/10/2020	Greenblatt, Matthew	0.3	Review materials re: Sackler family assets.
18	1/15/2020	Knechtel, Karl	3.3	Participate in meeting with professionals re: Sackler family's assets.
18	1/15/2020	Simms, Steven	3.3	Participate in meeting with professionals re: Sackler family's assets.
18	1/17/2020	Knechtel, Karl	3.3	Prepare summary re: Sackler family assets.
18	1/21/2020	Knechtel, Karl	3.1	Incorporate updates to summary re: Sackler family assets.
18	1/22/2020	Diaz, Matthew	1.2	Review the Sackler family balance sheets.
18	1/23/2020	Diaz, Matthew	1.1	Review the Sackler family asset statements.
18	1/27/2020	Simms, Steven	0.8	Review Sackler family assets documents.
18 Total			22.0	
19	1/2/2020	Knechtel, Karl	1.1	Review and update workplan.
19	1/2/2020	Simms, Steven	0.4	Correspond with the team re: outstanding issues.
19	1/3/2020	Simms, Steven	0.8	Review the updated team workplan.
19	1/6/2020	Knechtel, Karl	0.5	Review next steps.
19	1/7/2020	Knechtel, Karl	0.9	Participate in discussion with counsel re: information sharing.
19	1/14/2020	Eisenband, Michael	1.1	Review the updated status of the case.
19	1/16/2020	Eisenband, Michael	0.4	Correspond with the team re: next steps.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
19	1/21/2020	Knechtel, Karl	0.6	Participate in discussion with Houlihan re: due diligence update.
19	1/31/2020	Knechtel, Karl	0.9	Participate on call with counsel re: information sharing.
19 Total			6.7	
21	1/6/2020	Bromberg, Brian	1.0	Participate in a call with the committee professional group to discuss case next steps.
21	1/6/2020	Diaz, Matthew	1.0	Participate in a call with the committee professional group to discuss case next steps.
21	1/9/2020	Diaz, Matthew	1.5	Participate on the Committee call to discuss business plan due diligence, the protective order and other topics.
21	1/9/2020	Diaz, Matthew	1.7	Review documents in preparation for the Committee call.
21	1/9/2020	Knechtel, Karl	1.5	Participate on the Committee call to discuss business plan due diligence, the protective order and other topics.
21	1/9/2020	Suric, Emil	0.5	(Partial) Participate on the Committee call to discuss business plan due diligence, the protective order and other topics.
21	1/22/2020	Bromberg, Brian	1.4	Participate in a call with the Committee to discuss the London trip, emergency relief fund, the protective order, and other topics.
21	1/22/2020	Diaz, Matthew	0.4	Review materials in preparation for meeting with the Committee.
21	1/22/2020	Diaz, Matthew	1.4	Participate in a call with the Committee to discuss the London trip, emergency relief fund, the protective order, and other topics.
21	1/22/2020	Joffe, Steven	1.4	Participate in a call with the Committee to discuss the London trip, emergency relief fund, the protective order, and other topics.
21	1/22/2020	Kim, Ye Darm	1.4	Participate in a call with the Committee to discuss the London trip, emergency relief fund, the protective order, and other topics.
21	1/29/2020	Diaz, Matthew	1.0	Participate in a call with the Committee call to discuss the mediator, due diligence results, and other topics.
21	1/29/2020	Knechtel, Karl	1.0	Participate in a call with the Committee call to discuss the mediator, due diligence results, and other topics.
21 Total			15.2	
24	1/2/2020	Diaz, Matthew	1.1	Review the November 2019 Fee Statement.
24	1/2/2020	Tirabassi, Kathryn	1.8	Prepare the November 2019 Fee Statement.
24	1/2/2020	Tirabassi, Kathryn	2.2	Finalize November 2019 Fee Statement.
24	1/3/2020	Diaz, Matthew	0.5	Conduct a final review of the November 2019 Fee Statement.
24	1/3/2020	Tirabassi, Kathryn	0.4	Finalize November 2019 Fee Statement.
24	1/7/2020	Hellmund-Mora, Marili	0.5	Generate fee estimate in connection with reporting budget.
24	1/13/2020	Hellmund-Mora, Marili	0.5	Generate fee estimate in connection with reporting budget.
24	1/16/2020	Tirabassi, Kathryn	3.1	Prepare December 2019 Fee Statement.
24	1/17/2020	Tirabassi, Kathryn	3.3	Prepare December 2019 Fee Statement.
24	1/17/2020	Tirabassi, Kathryn	1.7	Continue to prepare December 2019 Fee Statement.
24	1/20/2020	Tirabassi, Kathryn	2.8	Prepare December 2019 Fee Statement.
24	1/21/2020	Tirabassi, Kathryn	1.3	Finalize December 2019 Fee Statement.
24	1/27/2020	Diaz, Matthew	0.9	Review the December 2019 Fee Statement.
24	1/27/2020	Tirabassi, Kathryn	0.8	Prepare December 2019 Fee Statement.
24 Total			20.9	
25	1/12/2020	Bromberg, Brian	9.5	Non-working travel time from NYC to London.
25	1/12/2020	Diaz, Matthew	3.5	Non-working travel time from NYC to London.
25	1/15/2020	Bromberg, Brian	1.3	Non-working travel time from London to Cambridge.
25	1/17/2020	Bromberg, Brian	1.5	Non-working travel time from Cambridge to London.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
25	1/17/2020	Diaz, Matthew	5.0	Non-working travel time from London to NYC.
25	1/18/2020	Bromberg, Brian	9.0	Non-working travel time from London to NYC.
25 Total			29.8	
28	1/2/2020	Bromberg, Brian	0.7	Prepare diligence summary.
28	1/2/2020	Bromberg, Brian	0.7	Update IAC work plan.
28	1/2/2020	Bromberg, Brian	0.9	Continue to review E&Y due diligence report.
28	1/2/2020	Bromberg, Brian	1.6	Discuss next steps with the team.
28	1/2/2020	Bromberg, Brian	1.8	Review IAC financial analysis.
28	1/2/2020	Bromberg, Brian	2.2	Review updated diligence tracker.
28	1/2/2020	Bromberg, Brian	2.4	Review E&Y due diligence report.
28	1/2/2020	Diaz, Matthew	1.2	Review the IAC open items list in preparation for trip to London.
28	1/2/2020	Diaz, Matthew	1.6	Discuss next steps with the team.
28	1/2/2020	Diaz, Matthew	1.7	Review the updated IAC financial information.
28	1/2/2020	Kim, Ye Darm	1.3	Incorporate updates to diligence tracker for received materials and additional requests for IAC management.
28	1/2/2020	Kim, Ye Darm	2.2	Continue to revise IAC diligence summaries.
28	1/2/2020	Kim, Ye Darm	2.3	Revise IAC diligence summaries.
28	1/2/2020	Kim, Ye Darm	2.6	Prepare analysis re: P&L forecast.
28	1/2/2020	Tsongidis, Theodoros	1.9	Review vendor due diligence report.
28	1/3/2020	Bromberg, Brian	0.5	Review materials in preparation for call re: IAC workplan.
28	1/3/2020	Bromberg, Brian	0.7	Review materials provided in dataroom.
28	1/3/2020	Bromberg, Brian	1.0	Participate in call with UCC, the Debtors and IAC advisors re: London meetings.
28	1/3/2020	Bromberg, Brian	1.7	Create agenda for London meetings.
28	1/3/2020	Bromberg, Brian	1.8	Review budget materials to refine diligence questions framework.
28	1/3/2020	Bromberg, Brian	2.1	Continue to create agenda for London meetings.
28	1/3/2020	Bromberg, Brian	2.2	Review diligence report question list.
28	1/3/2020	Diaz, Matthew	1.0	Participate in call with UCC, the Debtors and IAC advisors re: London meetings.
28	1/3/2020	Diaz, Matthew	1.4	Review the updated IAC information.
28	1/3/2020	Kim, Ye Darm	1.2	Prepare diligence summary for counsel.
28	1/3/2020	Kim, Ye Darm	1.6	Incorporate updates to P&L analysis.
28	1/3/2020	Kim, Ye Darm	2.2	Review key documents re: IAC diligence information.
28	1/3/2020	Kim, Ye Darm	2.7	Prepare list of diligence requests/questions for in-person London meetings.
28	1/3/2020	Kurtz, Emma	1.0	Participate in call with UCC, the Debtors and IAC advisors re: London meetings.
28	1/3/2020	Kurtz, Emma	3.1	Prepare analysis re: IAC P&Ls.
28	1/3/2020	Tsongidis, Theodoros	2.7	Prepare analysis re: vendor due diligence.
28	1/5/2020	Bromberg, Brian	1.3	Prepare comments re: diligence report.
28	1/6/2020	Broadhead, Gary	1.4	Review additional items added to the dataroom.
28	1/6/2020	Broadhead, Gary	2.3	Review updated IAC analysis.
28	1/6/2020	Bromberg, Brian	0.5	Prepare materials for Houlihan re: IACs.
28	1/6/2020	Bromberg, Brian	1.1	Participate in call with Management Revisions re: materials for London meetings.
28	1/6/2020	Bromberg, Brian	1.4	Prepare comments re: IAC diligence summary.
28	1/6/2020	Bromberg, Brian	1.8	Develop list of questions re: E&Y diligence report.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/6/2020	Bromberg, Brian	2.2	Develop meeting agenda for London meetings.
28	1/6/2020	Bromberg, Brian	2.3	Review due diligence report.
28	1/6/2020	Diaz, Matthew	1.0	Participate on call with S. Jamieson (Mundipharma) to discuss the information available for IAC review.
28	1/6/2020	Diaz, Matthew	2.7	Conduct a detailed review of IAC documents in preparation for the IAC meetings.
28	1/6/2020	Kim, Ye Darm	0.9	Incorporate updates to E&Y diligence requests for London meetings.
28	1/6/2020	Kim, Ye Darm	1.0	Participate on call with S. Jamieson (Mundipharma) to discuss the information available for IAC review.
28	1/6/2020	Kim, Ye Darm	1.1	Participate in call with Management Revisions re: materials for London meetings.
28	1/6/2020	Kim, Ye Darm	1.2	Prepare summary re: IAC litigation.
28	1/6/2020	Kim, Ye Darm	1.2	Prepare summary re: IACs in advance of London meetings.
28	1/6/2020	Kim, Ye Darm	1.4	Prepare summary re: compliance update.
28	1/6/2020	Kim, Ye Darm	1.9	Review compliance update from DLA.
28	1/6/2020	Kim, Ye Darm	2.2	Prepare update summary for the Committee re: London diligence meetings.
28	1/6/2020	Kurtz, Emma	0.2	Create detailed IAC diligence list.
28	1/6/2020	Kurtz, Emma	1.1	Participate in call with Management Revisions re: materials for London meetings.
28	1/6/2020	Kurtz, Emma	1.9	Prepare summaries re: IAC financials.
28	1/6/2020	Kurtz, Emma	2.1	Prepare analysis re: IAC financial information.
28	1/6/2020	Kurtz, Emma	2.2	Prepare analysis re: IAC financial information.
28	1/6/2020	Limoges Friend, Alexander	0.7	Review workplan and next steps.
28	1/6/2020	Limoges Friend, Alexander	2.1	Prepare analysis re: IAC commercial operations.
28	1/6/2020	Limoges Friend, Alexander	2.3	Review outstanding diligence questions.
28	1/6/2020	Limoges Friend, Alexander	2.9	Continue to prepare analysis re: IAC commercial operations.
28	1/6/2020	Tsongidis, Theodoros	0.7	Prepare additional analysis re: vendor due diligence.
28	1/6/2020	Tsongidis, Theodoros	1.4	Prepare summary re: vendor due diligence.
28	1/6/2020	Tsongidis, Theodoros	2.1	Review IAC financial information received.
28	1/6/2020	Tsongidis, Theodoros	2.4	Prepare summary re: IAC financial information.
28	1/7/2020	Broadhead, Gary	1.2	Review next steps re: IAC diligence.
28	1/7/2020	Broadhead, Gary	2.7	Review analysis prepared by the team re: IAC financial information.
28	1/7/2020	Bromberg, Brian	0.6	Participate on call with team to discuss and coordinate open items on the IAC review.
28	1/7/2020	Bromberg, Brian	1.8	Review latest information posted to IAC dataroom.
28	1/7/2020	Bromberg, Brian	1.8	Develop plan for London trip.
28	1/7/2020	Bromberg, Brian	2.3	Review IAC financial information provided for London meetings.
28	1/7/2020	Bromberg, Brian	2.7	Review DLA IAC compliance summary.
28	1/7/2020	Diaz, Matthew	0.5	Participate on call with Norton Rose to discuss the IAC open items.
28	1/7/2020	Diaz, Matthew	0.6	Participate on call with team to discuss and coordinate open items on the IAC review.
28	1/7/2020	Diaz, Matthew	1.1	Review IAC financial information.
28	1/7/2020	Kim, Ye Darm	0.5	Participate on call with Norton Rose to discuss the IAC open items.
28	1/7/2020	Kim, Ye Darm	1.2	Process revisions re: IAC update summary for Committee.
28	1/7/2020	Kim, Ye Darm	1.9	Revise P&L summary analysis.
28	1/7/2020	Kim, Ye Darm	1.9	Prepare additional diligence requests re: P&L analysis.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/7/2020	Kurtz, Emma	1.4	Incorporate comments to summaries re: IAC financials.
28	1/7/2020	Kurtz, Emma	3.2	Incorporate updates to summaries re: IAC financial information.
28	1/7/2020	Kurtz, Emma	3.3	Prepare additional analysis re: IAC financials.
28	1/7/2020	Limoges Friend, Alexander	2.0	Prepare questions re: IAC commercial operations.
28	1/7/2020	Limoges Friend, Alexander	2.8	Continue to prepare summary re: IAC commercial operations.
28	1/7/2020	Limoges Friend, Alexander	3.2	Prepare summary re: IAC commercial operations.
28	1/7/2020	Tsongidis, Theodoros	0.5	Prepare questions re: IAC financials.
28	1/7/2020	Tsongidis, Theodoros	1.6	Continue to prepare analysis re: IAC financial results.
28	1/7/2020	Tsongidis, Theodoros	2.8	Prepare summary re: IAC financial results.
28	1/7/2020	Tsongidis, Theodoros	3.1	Prepare analysis re: IAC financial results.
28	1/8/2020	Broadhead, Gary	2.1	Review updated diligence question list.
28	1/8/2020	Broadhead, Gary	2.8	Analyze financial performance of IACs.
28	1/8/2020	Bromberg, Brian	0.5	Participate on call with case advisors re: London meeting schedule.
28	1/8/2020	Bromberg, Brian	1.3	Prepare comments re: IAC summary update.
28	1/8/2020	Bromberg, Brian	1.3	Review IAC analysis prepared in advance of London meetings.
28	1/8/2020	Bromberg, Brian	1.3	Revise question list for E&Y.
28	1/8/2020	Bromberg, Brian	1.4	Review E&Y vendor due diligence report.
28	1/8/2020	Bromberg, Brian	1.6	Prepare summary re: IAC financial information.
28	1/8/2020	Bromberg, Brian	2.2	Review latest information posted to IAC dataroom.
28	1/8/2020	Bromberg, Brian	2.8	Participate in meeting with DLA re: compliance.
28	1/8/2020	Diaz, Matthew	0.5	Correspond with Houlihan re: preparation for IAC meetings.
28	1/8/2020	Diaz, Matthew	1.1	Prepare comments re: question list for the IAC meeting.
28	1/8/2020	Diaz, Matthew	1.6	Review materials provided by DLA to prepare for the DLA meeting re: compliance.
28	1/8/2020	Diaz, Matthew	2.8	Participate in meeting with DLA re: compliance.
28	1/8/2020	Kim, Ye Darm	1.4	Process further revisions to business update summary.
28	1/8/2020	Kim, Ye Darm	1.8	Review IAC financial analysis.
28	1/8/2020	Kim, Ye Darm	1.9	Prepare additional P&L analysis.
28	1/8/2020	Kim, Ye Darm	2.4	Incorporate further revisions to summary re: business update.
28	1/8/2020	Kurtz, Emma	1.2	Incorporate further updates to IAC financial summaries.
28	1/8/2020	Kurtz, Emma	1.4	Incorporate updates to summaries re: IAC financials.
28	1/8/2020	Kurtz, Emma	1.6	Continue to prepare further analysis re: IAC financial information.
28	1/8/2020	Kurtz, Emma	2.4	Prepare further analysis re: IAC financial information.
28	1/8/2020	Limoges Friend, Alexander	2.1	Review financial information in preparation for upcoming meetings.
28	1/8/2020	Limoges Friend, Alexander	2.9	Prepare questions re: IAC technical operations.
28	1/8/2020	Limoges Friend, Alexander	3.2	Review technical operations information in preparation for upcoming meetings.
28	1/8/2020	Tsongidis, Theodoros	0.6	Continue to prepare additional analysis re: IAC financial information.
28	1/8/2020	Tsongidis, Theodoros	1.8	Continue to prepare summary re: vendor due diligence.
28	1/8/2020	Tsongidis, Theodoros	2.9	Prepare summary re: vendor due diligence.
28	1/8/2020	Tsongidis, Theodoros	3.0	Prepare additional analysis re: IAC financial information.
28	1/9/2020	Broadhead, Gary	2.4	Review updated analysis prepared by the team re: IAC financial information.
28	1/9/2020	Broadhead, Gary	3.1	Prepare detailed comments re: IAC financial analysis.
28	1/9/2020	Bromberg, Brian	1.0	Participate on call with Houlihan to prepare for the London meetings.
28	1/9/2020	Bromberg, Brian	1.2	Revise question list for E&Y.
28	1/9/2020	Bromberg, Brian	1.2	Review updated IAC summaries.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/9/2020	Bromberg, Brian	3.4	Review materials provided in dataroom for London meetings.
28	1/9/2020	Diaz, Matthew	1.0	Participate on call with Houlihan to prepare for the London meetings.
28	1/9/2020	Diaz, Matthew	2.7	Review IAC summaries to prepare for the in person London meetings.
28	1/9/2020	Kim, Ye Darm	0.6	Incorporate further updates to business update summary.
28	1/9/2020	Kim, Ye Darm	1.0	Participate on call with Houlihan to prepare for the London meetings.
28	1/9/2020	Kim, Ye Darm	1.8	Continue to prepare analysis re: business plan P&Ls.
28	1/9/2020	Kim, Ye Darm	2.2	Prepare additional P&L analysis.
28	1/9/2020	Kurtz, Emma	0.8	Incorporate updates to IAC financial summaries.
28	1/9/2020	Kurtz, Emma	1.1	Continue to prepare additional summaries re: IAC financial information.
28	1/9/2020	Kurtz, Emma	2.7	Prepare additional summaries re: IAC financial information.
28	1/9/2020	Kurtz, Emma	2.9	Prepare further analysis re: IAC financial performance.
28	1/9/2020	Kurtz, Emma	3.3	Prepare analysis re: financial performance of IACs.
28	1/9/2020	Limoges Friend, Alexander	0.2	Review updated workplan.
28	1/9/2020	Limoges Friend, Alexander	0.8	Incorporate updates to outstanding questions.
28	1/9/2020	Limoges Friend, Alexander	2.8	Continue to prepare summaries re: technical operations in preparation for meetings.
28	1/9/2020	Limoges Friend, Alexander	3.2	Prepare summaries re: technical operations in preparation for meetings.
28	1/9/2020	Tsongidis, Theodoros	2.2	Prepare summary re: IAC financial analysis.
28	1/9/2020	Tsongidis, Theodoros	2.9	Prepare financial analysis re: IACs.
28	1/9/2020	Tsongidis, Theodoros	3.3	Continue to prepare financial analysis re: IACs.
28	1/10/2020	Bradley, Adam	2.1	Review information received in the dataroom.
28	1/10/2020	Broadhead, Gary	2.1	Review additional items added to the dataroom.
28	1/10/2020	Broadhead, Gary	2.3	Review updated analysis re: IAC financial performance.
28	1/10/2020	Bromberg, Brian	0.8	Coordinate logistics with the team re: London meetings.
28	1/10/2020	Bromberg, Brian	2.3	Review new dataroom documents.
28	1/10/2020	Bromberg, Brian	3.3	Review IAC analysis prepared for London meetings.
28	1/10/2020	Diaz, Matthew	1.3	Review open items and related next steps on the IAC review.
28	1/10/2020	Diaz, Matthew	2.9	Conduct further review IAC materials to prepare for the London business plan meetings.
28	1/10/2020	Kim, Ye Darm	2.4	Prepare summary re: P&L forecasts.
28	1/10/2020	Kim, Ye Darm	2.5	Review additional historical business plan materials from country heads.
28	1/10/2020	Kim, Ye Darm	2.8	Prepare product sales analysis.
28	1/10/2020	Kurtz, Emma	2.8	Prepare additional analysis re: IAC financial performance.
28	1/10/2020	Kurtz, Emma	2.9	Incorporate comments to financial performance summaries.
28	1/10/2020	Limoges Friend, Alexander	2.2	Continue to analyze IAC financial information.
28	1/10/2020	Limoges Friend, Alexander	2.8	Analyze IAC financial information.
28	1/10/2020	Limoges Friend, Alexander	3.4	Incorporate updates to summaries re: technical operations in preparation for meetings.
28	1/10/2020	Tsongidis, Theodoros	1.9	Continue to prepare additional analysis re: IAC financials.
28	1/10/2020	Tsongidis, Theodoros	2.8	Review updated financial information received.
28	1/10/2020	Tsongidis, Theodoros	3.1	Prepare additional analysis re: IAC financials.
28	1/10/2020	Vohra, Paul	2.0	Review updated documents received from the data room.
28	1/12/2020	Bromberg, Brian	1.7	Review provided documents for London meetings.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/12/2020	Diaz, Matthew	2.4	Review materials in preparation for the in-person IAC meetings in London.
28	1/13/2020	Broadhead, Gary	1.4	Review materials received in preparation for meetings.
28	1/13/2020	Broadhead, Gary	1.9	Participate in meeting with the P. Mazas (Mundipharma CIO).
28	1/13/2020	Broadhead, Gary	2.0	Participate in meeting with the Mundipharma's global head of intellectual property.
28	1/13/2020	Broadhead, Gary	2.2	Participate in meeting with the S. Lopez (Mundipharma head of Switzerland/Austria).
28	1/13/2020	Broadhead, Gary	2.3	Participate in meeting with the Mundipharma's global general counsel.
28	1/13/2020	Bromberg, Brian	0.5	Review IT materials.
28	1/13/2020	Bromberg, Brian	1.9	Participate in meeting with the P. Mazas (Mundipharma CIO).
28	1/13/2020	Bromberg, Brian	2.0	Participate in meeting with the Mundipharma's global head of intellectual property.
28	1/13/2020	Bromberg, Brian	2.2	Participate in meeting with the S. Lopez (Mundipharma head of Switzerland/Austria).
28	1/13/2020	Bromberg, Brian	2.3	Participate in meeting with the Mundipharma's global general counsel.
28	1/13/2020	Diaz, Matthew	1.9	Review materials to prepare for upcoming meetings.
28	1/13/2020	Diaz, Matthew	2.0	Participate in meeting with the Mundipharma's global head of intellectual property.
28	1/13/2020	Diaz, Matthew	2.2	Prepare summary re: meetings in London.
28	1/13/2020	Diaz, Matthew	2.2	Participate in meeting with the S. Lopez (Mundipharma head of Switzerland/Austria).
28	1/13/2020	Diaz, Matthew	2.3	Participate in meeting with the Mundipharma's global general counsel.
28	1/13/2020	Limoges Friend, Alexander	1.9	Participate in meeting with the P. Mazas (Mundipharma CIO).
28	1/13/2020	Limoges Friend, Alexander	2.1	Prepare analysis re: financials.
28	1/13/2020	Limoges Friend, Alexander	2.2	Participate in meeting with the S. Lopez (Mundipharma head of Switzerland/Austria).
28	1/13/2020	Limoges Friend, Alexander	2.4	Continue to prepare analysis re: financials.
28	1/13/2020	Tsongidis, Theodoros	2.1	Continue to prepare summary re: IAC financials.
28	1/13/2020	Tsongidis, Theodoros	2.9	Prepare summary re: IAC financials.
28	1/13/2020	Tsongidis, Theodoros	3.2	Analyze IAC financial information.
28	1/14/2020	Broadhead, Gary	2.7	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Broadhead, Gary	3.1	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Broadhead, Gary	3.2	Participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Bromberg, Brian	0.9	Review provided documents in preparation for upcoming meetings.
28	1/14/2020	Bromberg, Brian	2.7	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Bromberg, Brian	3.1	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Bromberg, Brian	3.2	Participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Diaz, Matthew	2.7	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Diaz, Matthew	3.1	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Diaz, Matthew	3.2	Participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Limoges Friend, Alexander	2.7	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Limoges Friend, Alexander	3.1	Continue to participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Limoges Friend, Alexander	3.2	Participate in meeting with S. Jamieson (Mundipharma).
28	1/14/2020	Tsongidis, Theodoros	2.9	Incorporate updates to analysis re: IAC financial information.
28	1/14/2020	Tsongidis, Theodoros	3.1	Analyze further IAC financial information.
28	1/15/2020	Broadhead, Gary	1.8	Participate in meeting with Mundipharma's global head of quality.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/15/2020	Broadhead, Gary	2.2	Participate in meeting with the Mundipharma's head of Belgium/Netherlands.
28	1/15/2020	Broadhead, Gary	2.3	Participate in meeting with Mundipharma's Italy commercial lead.
28	1/15/2020	Broadhead, Gary	2.3	Participate in meeting with Mundipharma's Spain commercial lead.
28	1/15/2020	Bromberg, Brian	0.8	Review provided documents in preparation for meetings.
28	1/15/2020	Bromberg, Brian	1.8	Participate in meeting with Mundipharma's global head of quality.
28	1/15/2020	Bromberg, Brian	2.2	Participate in meeting with the Mundipharma's head of Belgium/Netherlands.
28	1/15/2020	Bromberg, Brian	2.3	Participate in meeting with Mundipharma's Spain commercial lead.
28	1/15/2020	Bromberg, Brian	2.3	Participate in meeting with Mundipharma's Italy commercial lead.
28	1/15/2020	Diaz, Matthew	1.8	Participate in meeting with Mundipharma's global head of quality.
28	1/15/2020	Diaz, Matthew	2.2	Participate in meeting with the Mundipharma's head of Belgium/Netherlands.
28	1/15/2020	Diaz, Matthew	2.3	Participate in meeting with Mundipharma's Spain commercial lead.
28	1/15/2020	Diaz, Matthew	2.3	Participate in meeting with Mundipharma's Italy commercial lead.
28	1/15/2020	Tsongidis, Theodoros	2.3	Review materials in preparation for upcoming meetings.
28	1/16/2020	Broadhead, Gary	1.8	Participate in tour of manufacturing plant in Cambridge.
28	1/16/2020	Broadhead, Gary	2.1	Participate in meeting with the Mundipharma's head of UK operations.
28	1/16/2020	Broadhead, Gary	2.2	Participate in meeting with Mundipharma's head of Germany operations.
28	1/16/2020	Broadhead, Gary	2.4	Participate in meeting with Mundipharma's head of technical operations.
28	1/16/2020	Bromberg, Brian	0.8	Review documents in preparation for meetings.
28	1/16/2020	Bromberg, Brian	1.8	Participate in tour of manufacturing plant in Cambridge.
28	1/16/2020	Bromberg, Brian	2.1	Participate in meeting with the Mundipharma's head of UK operations.
28	1/16/2020	Bromberg, Brian	2.2	Participate in meeting with Mundipharma's head of Germany operations.
28	1/16/2020	Bromberg, Brian	2.4	Participate in meeting with Mundipharma's head of technical operations.
28	1/16/2020	Diaz, Matthew	1.8	Participate in tour of manufacturing plant in Cambridge.
28	1/16/2020	Diaz, Matthew	2.1	Participate in meeting with the Mundipharma's head of UK operations.
28	1/16/2020	Diaz, Matthew	2.2	Participate in meeting with Mundipharma's head of Germany operations.
28	1/16/2020	Diaz, Matthew	2.4	Review materials in preparation for meetings.
28	1/16/2020	Diaz, Matthew	2.4	Participate in meeting with Mundipharma's head of technical operations.
28	1/16/2020	Limoges Friend, Alexander	3.2	Prepare analysis re: IAC financials.
28	1/16/2020	Tsongidis, Theodoros	1.8	Participate in tour of manufacturing plant in Cambridge.
28	1/16/2020	Tsongidis, Theodoros	2.1	Participate in meeting with the Mundipharma's head of UK operations.
28	1/16/2020	Tsongidis, Theodoros	2.2	Participate in meeting with Mundipharma's head of Germany operations.
28	1/16/2020	Tsongidis, Theodoros	2.4	Participate in meeting with Mundipharma's head of technical operations.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/17/2020	Bradley, Adam	1.8	Participate in meeting with Mundipharma's France commercial lead.
28	1/17/2020	Bradley, Adam	2.6	Review materials in preparation for upcoming meetings.
28	1/17/2020	Bradley, Adam	3.4	Participate in meeting with Mundipharma Europe CEO and VP of Strategy.
28	1/17/2020	Broadhead, Gary	1.8	Participate in meeting with Mundipharma's France commercial lead.
28	1/17/2020	Broadhead, Gary	2.1	Review additional materials received in preparation for meetings.
28	1/17/2020	Broadhead, Gary	3.4	Participate in meeting with Mundipharma Europe CEO and VP of Strategy.
28	1/17/2020	Bromberg, Brian	0.3	Participate in meeting with Houlihan re: diligence meeting follow ups.
28	1/17/2020	Bromberg, Brian	1.8	Participate in meeting with Mundipharma's France commercial lead.
28	1/17/2020	Bromberg, Brian	3.4	Participate in meeting with Mundipharma Europe CEO and VP of Strategy.
28	1/17/2020	Diaz, Matthew	0.3	Participate in meeting with Houlihan re: diligence meeting follow ups.
28	1/17/2020	Diaz, Matthew	0.6	Draft correspondence to the Committee's professionals in connection with an update on London diligence.
28	1/17/2020	Diaz, Matthew	1.8	Participate in meeting with Mundipharma's France commercial lead.
28	1/17/2020	Diaz, Matthew	3.4	Participate in meeting with Mundipharma Europe CEO and VP of Strategy.
28	1/17/2020	Diaz, Matthew	3.4	Review notes and develop next steps on IAC due diligence.
28	1/17/2020	Limoges Friend, Alexander	1.9	Prepare analysis re: European financials.
28	1/17/2020	Tsongidis, Theodoros	1.0	Review financial information received at meetings.
28	1/20/2020	Broadhead, Gary	2.3	Review analysis re: London meetings.
28	1/20/2020	Broadhead, Gary	2.7	Review summary update re: London meetings.
28	1/20/2020	Bromberg, Brian	0.8	Review Houlihan summary re: London meetings.
28	1/20/2020	Bromberg, Brian	1.3	Create diligence follow up list from London meetings.
28	1/20/2020	Diaz, Matthew	1.0	Review the IAC due diligence presentation.
28	1/20/2020	Limoges Friend, Alexander	2.2	Continue to prepare further analysis re: European financials.
28	1/20/2020	Limoges Friend, Alexander	2.8	Prepare summaries re: European financials.
28	1/20/2020	Limoges Friend, Alexander	2.9	Prepare further analysis re: European financials.
28	1/20/2020	Shah, Jayshree	2.3	Review outstanding IAC analysis.
28	1/20/2020	Shah, Jayshree	2.7	Prepare summary re: IAC diligence meetings.
28	1/20/2020	Shah, Jayshree	3.1	Review financial information received at meetings.
28	1/20/2020	Tsongidis, Theodoros	2.2	Prepare updated summary re: financial analysis.
28	1/20/2020	Tsongidis, Theodoros	3.0	Incorporate updates to financial analysis following meetings.
28	1/20/2020	Tsongidis, Theodoros	3.0	Continue to incorporate updates to financial analysis following meetings.
28	1/21/2020	Broadhead, Gary	2.8	Review IAC financial performance analysis.
28	1/21/2020	Bromberg, Brian	0.4	Participate on call with Houlihan to discuss the due diligence next steps.
28	1/21/2020	Bromberg, Brian	0.9	Participate in a call with the professionals to discuss the results of the London due diligence.
28	1/21/2020	Bromberg, Brian	1.3	Review new documents uploaded to dataroom.
28	1/21/2020	Bromberg, Brian	1.5	Review IAC financial information provided for London meetings.
28	1/21/2020	Bromberg, Brian	1.5	Compile follow up requests after London meetings.
28	1/21/2020	Bromberg, Brian	1.8	Prepare questions re: E&Y report.
28	1/21/2020	Bromberg, Brian	1.9	Continue to compile follow up IAC requests after London meetings.
28	1/21/2020	Bromberg, Brian	2.1	Review IAC financial information.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/21/2020	Diaz, Matthew	0.4	Participate on call with Houlihan to discuss the due diligence next steps.
28	1/21/2020	Diaz, Matthew	0.9	Participate in a call with the professionals to discuss the results of the London due diligence.
28	1/21/2020	Diaz, Matthew	2.7	Conduct a detailed review of notes from diligence meetings to determine next steps and open items.
28	1/21/2020	Kim, Ye Darm	0.4	Participate on call with Houlihan to discuss the due diligence next steps.
28	1/21/2020	Kim, Ye Darm	0.7	Review Houlihan update re: diligence in London.
28	1/21/2020	Kim, Ye Darm	0.9	Participate in a call with the professionals to discuss the results of the London due diligence.
28	1/21/2020	Kim, Ye Darm	0.9	Incorporate updates to diligence questions.
28	1/21/2020	Kim, Ye Darm	1.2	Review P&L data.
28	1/21/2020	Kim, Ye Darm	1.6	Review P&L bridge analysis.
28	1/21/2020	Kurtz, Emma	0.4	Incorporate updates to IAC diligence tracker following London meetings.
28	1/21/2020	Limoges Friend, Alexander	1.9	Continue to incorporate updates to summaries re: European financials.
28	1/21/2020	Limoges Friend, Alexander	1.9	Continue to prepare further analysis re: IAC financials.
28	1/21/2020	Limoges Friend, Alexander	3.1	Incorporate updates to summaries re: European financials.
28	1/21/2020	Limoges Friend, Alexander	3.2	Prepare further analysis re: IAC financials.
28	1/21/2020	Shah, Jayshree	2.8	Prepare analysis re: business plan.
28	1/21/2020	Shah, Jayshree	2.9	Continue to review financial information received at meetings.
28	1/21/2020	Shah, Jayshree	3.2	Prepare summary re: financial information received at meetings.
28	1/21/2020	Tsongidis, Theodoros	2.3	Continue to incorporate updates to IAC financial analysis.
28	1/21/2020	Tsongidis, Theodoros	2.8	Incorporate updates to IAC financial analysis.
28	1/21/2020	Tsongidis, Theodoros	2.9	Continue to incorporate updates to IAC financial analysis.
28	1/22/2020	Broadhead, Gary	2.9	Review IAC financial performance summaries.
28	1/22/2020	Bromberg, Brian	0.5	Review IAC financial analysis.
28	1/22/2020	Bromberg, Brian	1.1	Review diligence update for counsel.
28	1/22/2020	Bromberg, Brian	1.7	Prepare further diligence requests re: IACs.
28	1/22/2020	Bromberg, Brian	2.1	Review updated IAC financial summaries.
28	1/22/2020	Bromberg, Brian	2.2	Prepare updated IAC workplan.
28	1/22/2020	Diaz, Matthew	1.6	Review the updated IAC request list.
28	1/22/2020	Kim, Ye Darm	0.4	Review draft of emergency relief fund proposal.
28	1/22/2020	Kim, Ye Darm	0.6	Review IAC business plan workplan.
28	1/22/2020	Kim, Ye Darm	3.3	Prepare analysis re: P&L.
28	1/22/2020	Limoges Friend, Alexander	2.8	Continue to incorporate updates to summaries re: IAC financials.
28	1/22/2020	Limoges Friend, Alexander	3.1	Incorporate updates to summaries re: IAC financials.
28	1/22/2020	Limoges Friend, Alexander	3.1	Analyze financial performance of IACs.
28	1/22/2020	Shah, Jayshree	1.6	Continue to conduct analysis re: IAC business operations.
28	1/22/2020	Shah, Jayshree	2.1	Prepare summary re: IAC operations research.
28	1/22/2020	Shah, Jayshree	2.3	Conduct analysis re: IAC business operations.
28	1/22/2020	Tsongidis, Theodoros	2.7	Incorporate updates to IAC financial summaries.
28	1/22/2020	Tsongidis, Theodoros	3.2	Continue to incorporate updates to IAC financial summaries.
28	1/23/2020	Bradley, Adam	2.1	Review analysis prepared by the team re: IAC financial information.
28	1/23/2020	Broadhead, Gary	2.6	Prepare comments re: IAC financial performance summaries.
28	1/23/2020	Bromberg, Brian	0.8	Finalize question list re: E&Y report.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/23/2020	Bromberg, Brian	0.9	Prepare comments re: IAC financial information summaries.
28	1/23/2020	Bromberg, Brian	1.8	Create topic list for meeting with CFO.
28	1/23/2020	Bromberg, Brian	2.6	Review IAC financial information provided.
28	1/23/2020	Diaz, Matthew	0.5	Participate on call with Alix to review next steps re: IAC analysis.
28	1/23/2020	Kim, Ye Darm	0.7	Prepare summary re: P&L analysis.
28	1/23/2020	Kim, Ye Darm	0.8	Review discussion topics for potential call with global CFO.
28	1/23/2020	Kim, Ye Darm	1.1	Continue to prepare further analysis re: P&Ls.
28	1/23/2020	Kim, Ye Darm	3.1	Prepare further analysis re: P&Ls.
28	1/23/2020	Limoges Friend, Alexander	2.9	Continue to analyze financial performance of IACs.
28	1/23/2020	Limoges Friend, Alexander	2.9	Continue to prepare summaries re: financial performance of IACs.
28	1/23/2020	Limoges Friend, Alexander	3.1	Prepare summaries re: financial performance of IACs.
28	1/23/2020	Tsongidis, Theodoros	2.7	Incorporate comments re: IAC financial summaries.
28	1/23/2020	Tsongidis, Theodoros	3.1	Incorporate comments re: IAC financial analysis.
28	1/24/2020	Broadhead, Gary	3.1	Review updated version of IAC financial performance summaries.
28	1/24/2020	Bromberg, Brian	0.5	Finalize question list re: E&Y report.
28	1/24/2020	Bromberg, Brian	0.5	Participate in call with S. Jamieson (Mundipharma) re: document request list.
28	1/24/2020	Bromberg, Brian	2.0	Prepare for call with S. Jamieson (Mundipharma).
28	1/24/2020	Diaz, Matthew	0.7	Review the IAC open items list and related next steps.
28	1/24/2020	Kim, Ye Darm	0.5	Participate in call with S. Jamieson (Mundipharma) re: document request list.
28	1/24/2020	Kim, Ye Darm	0.6	Review list of consolidated question list.
28	1/24/2020	Kim, Ye Darm	2.1	Review IAC summaries.
28	1/24/2020	Kurtz, Emma	0.5	Participate in call with S. Jamieson (Mundipharma) re: document request list.
28	1/24/2020	Limoges Friend, Alexander	0.5	Participate in call with S. Jamieson (Mundipharma) re: document request list.
28	1/24/2020	Limoges Friend, Alexander	2.9	Continue to incorporate comments to summaries re: financial performance of IACs.
28	1/24/2020	Limoges Friend, Alexander	3.1	Incorporate comments to summaries re: financial performance of IACs.
28	1/24/2020	Tsongidis, Theodoros	0.5	Participate in call with S. Jamieson (Mundipharma) re: document request list.
28	1/27/2020	Bromberg, Brian	0.9	Prepare comments re: IAC entity analysis.
28	1/27/2020	Bromberg, Brian	2.4	Prepare updated diligence questions.
28	1/27/2020	Bromberg, Brian	3.2	Review IAC entity analysis.
28	1/27/2020	Diaz, Matthew	0.6	Review next steps re: call with S. Jamieson (Mundipharma).
28	1/27/2020	Diaz, Matthew	1.0	Participate in a call with counsel to discuss the IAC next steps.
28	1/27/2020	Kim, Ye Darm	0.8	Incorporate updates to diligence tracker for new requests for the IACs.
28	1/27/2020	Kim, Ye Darm	0.9	Prepare summary re: IAC financials.
28	1/27/2020	Kim, Ye Darm	1.2	Prepare analysis re: IAC financials.
28	1/27/2020	Kim, Ye Darm	2.1	Continue to prepare analysis re: IAC financials.
28	1/27/2020	Limoges Friend, Alexander	2.1	Review new information received in the dataroom.
28	1/28/2020	Bromberg, Brian	0.6	Participate on call with Alix to discuss next steps re: IACs.
28	1/28/2020	Bromberg, Brian	0.7	Develop agenda for call with Mundipharma CFO.
28	1/28/2020	Bromberg, Brian	1.8	Continue to review IAC entity analysis.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	1/28/2020	Bromberg, Brian	1.8	Prepare further comments re: IAC entity analysis.
28	1/28/2020	Bromberg, Brian	2.3	Review IAC financial information.
28	1/28/2020	Diaz, Matthew	0.6	Participate on call with Alix to discuss next steps re: IACs.
28	1/28/2020	Diaz, Matthew	1.9	Review the updated IAC analysis.
28	1/28/2020	Kim, Ye Darm	1.1	Prepare summary re: IAC financials.
28	1/29/2020	Bromberg, Brian	0.5	Participate in call with Alix re: Singapore diligence trip.
28	1/29/2020	Bromberg, Brian	1.0	Review E&Y vendor due diligence report.
28	1/29/2020	Bromberg, Brian	1.3	Incorporate updates to diligence list.
28	1/29/2020	Bromberg, Brian	2.6	Prepare summary re: IAC diligence update.
28	1/29/2020	Bromberg, Brian	2.7	Review further financial information received.
28	1/29/2020	Diaz, Matthew	2.3	Review the updated IAC analysis.
28	1/29/2020	Kurtz, Emma	1.4	Prepare summaries re: IAC entities.
28	1/29/2020	Kurtz, Emma	1.9	Continue to prepare analysis re: IAC entities.
28	1/29/2020	Kurtz, Emma	2.7	Prepare analysis re: IAC entities.
28	1/30/2020	Bromberg, Brian	0.9	Review materials in preparation for call with Mundipharma CFO.
28	1/30/2020	Bromberg, Brian	1.1	Review analysis re: IAC financials.
28	1/30/2020	Bromberg, Brian	1.3	Review next steps re: IAC financial analysis.
28	1/30/2020	Bromberg, Brian	1.3	Develop topics to discuss re: Singapore diligence trip.
28	1/30/2020	Bromberg, Brian	1.7	Prepare further comments re: IAC entity analysis.
28	1/30/2020	Kim, Ye Darm	1.6	Prepare summary re: IACs.
28	1/30/2020	Kurtz, Emma	2.6	Continue to prepare additional summaries re: IAC entities.
28	1/30/2020	Kurtz, Emma	3.4	Prepare additional summaries re: IAC entities.
28	1/30/2020	Limoges Friend, Alexander	2.2	Review information in preparation for call with A. Breabout (Mundipharma).
28	1/31/2020	Bradley, Adam	1.0	Participate on call with A. Breabout (Mundipharma).
28	1/31/2020	Broadhead, Gary	1.0	Participate on call with A. Breabout (Mundipharma).
28	1/31/2020	Bromberg, Brian	0.5	Review diligence requests re: Singapore meetings.
28	1/31/2020	Bromberg, Brian	0.9	Review updated financial information received.
28	1/31/2020	Bromberg, Brian	1.0	Participate on call with A. Breabout (Mundipharma).
28	1/31/2020	Bromberg, Brian	1.3	Review materials in preparation for call with Mundipharma CFO.
28	1/31/2020	Bromberg, Brian	2.8	Finalize IAC entity summary.
28	1/31/2020	Bromberg, Brian	2.8	Review financial information re: IACs.
28	1/31/2020	Kim, Ye Darm	2.1	Prepare analysis re: IAC operations.
28	1/31/2020	Kim, Ye Darm	2.2	Prepare summary re: IAC entities.
28	1/31/2020	Kurtz, Emma	1.0	Participate on call with A. Breabout (Mundipharma).
28	1/31/2020	Kurtz, Emma	1.4	Prepare additional analysis re: IAC financial performance.
28	1/31/2020	Kurtz, Emma	2.7	Continue to prepare additional analysis re: IAC financial performance.
28	1/31/2020	Limoges Friend, Alexander	1.0	Participate on call with A. Breabout (Mundipharma).
28	1/31/2020	Limoges Friend, Alexander	2.8	Prepare further analysis re: financial performance of IACs.
28	1/31/2020	Limoges Friend, Alexander	2.9	Continue to prepare further analysis re: financial performance of IACs.
28 Total			749.5	
Grand Total			1,004.4	

EXHIBIT D

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF EXPENSES
FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020**

Expense Type	Amount
Airfare	\$ 4,900.90
Lodging	4,264.56
Transportation	1,988.38
Working Meals ¹	280.92
Other	96.08
Grand Total²	\$ 11,530.84

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.
2. Expenses incurred internationally have been translated to USD using the relevant spot rate.

EXHIBIT E

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

EXPENSE DETAIL

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Date	Professional	Expense Type	Expense Detail	Amount
1/12/2020	Bromberg, Brian	Airfare	Airfare - Coach Equivalent, Brian Bromberg, EWR - LHR, 01/12/2020 - 01/18/2020. Airfare for travel to/from London for case meetings.	\$ 2,450.45
1/12/2020	Diaz, Matthew	Airfare	Airfare - Coach Equivalent, Matthew Diaz, JFK - LHR, 01/12/2020 - 01/17/2020. Airfare for travel to/from London for case meetings.	2,450.45
Airfare Total				\$ 4,900.90
1/12/2020	Bromberg, Brian	Lodging	Lodging - Brian Bromberg 01/12/2020 - 01/15/2020. Hotel in London while traveling for case meetings.	1,142.71
1/12/2020	Diaz, Matthew	Lodging	Lodging - Matthew Diaz 01/12/2020 - 01/15/2020. Hotel in London while traveling for case meetings.	1,129.36
1/15/2020	Broadhead, Gary	Lodging	Lodging - Gary Broadhead 01/15/2020 - 01/17/2020. Hotel in Cambridge while traveling for case meetings.	583.09
1/15/2020	Bromberg, Brian	Lodging	Breakfast at hotel in London while traveling for case meetings.	18.04
1/15/2020	Bromberg, Brian	Lodging	Lodging - Brian Bromberg 01/15/2020 - 01/17/2020. Hotel in Cambridge while traveling for case meetings.	601.88
1/15/2020	Diaz, Matthew	Lodging	Breakfast at hotel in London while traveling for case meetings.	22.10
1/15/2020	Diaz, Matthew	Lodging	Lodging - Matthew Diaz 01/15/2020 - 01/17/2020. Hotel in Cambridge while traveling for case meetings.	625.55
1/16/2020	Diaz, Matthew	Lodging	Breakfast at hotel in Cambridge while traveling for case meetings.	22.14
1/17/2020	Bromberg, Brian	Lodging	Lodging - Brian Bromberg 01/17/2020 - 01/18/2020. Hotel in London while traveling for case meetings.	119.69
Lodging Total				\$ 4,264.56
11/19/2019	Diaz, Matthew	Transportation	Taxi to White Plains to attend a court hearing	120.08
11/19/2019	Diaz, Matthew	Transportation	Taxi from White Plains from attending a court hearing	60.63
12/5/2019	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	26.97
12/6/2019	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	22.84
12/8/2019	Diaz, Matthew	Transportation	Taxi to the office while working on the weekend.	14.95
12/10/2019	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	43.25
12/10/2019	Diaz, Matthew	Transportation	Taxi home from the office after working late on the case.	11.76
12/11/2019	Kim, Ye Darm	Transportation	Taxi home from the office after working late on the case.	20.04
12/11/2019	Shapiro, Jill	Transportation	Taxi home from the office after working late on the case.	12.36
12/12/2019	Kim, Ye Darm	Transportation	Taxi home from the office after working late on the case.	12.34
12/13/2019	Bingham, Anthony	Transportation	Taxi from the hotel to case meetings.	65.82
12/16/2019	Kim, Ye Darm	Transportation	Taxi home from the office after working late on the case.	13.00
12/17/2019	Kim, Ye Darm	Transportation	Taxi home from the office after working late on the case.	12.73
12/19/2019	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	25.67
1/3/2020	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	25.55
1/3/2020	Kim, Ye Darm	Transportation	Taxi home from the office after working late on the case.	13.04
1/4/2020	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	26.08
1/7/2020	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	23.50
1/7/2020	Kim, Ye Darm	Transportation	Taxi home from the office after working late on the case.	11.74
1/7/2020	Kurtz, Emma	Transportation	Taxi home from the office after working late on the case.	21.92
1/8/2020	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	24.36
1/9/2020	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	24.51
1/9/2020	Kurtz, Emma	Transportation	Taxi home from the office after working late on the case.	23.42
1/12/2020	Bromberg, Brian	Transportation	Taxi to the airport while traveling for case meetings.	67.25
1/12/2020	Bromberg, Brian	Transportation	Taxi to the hotel while traveling for case meetings.	124.33
1/12/2020	Diaz, Matthew	Transportation	Taxi to the airport while traveling for case meetings.	70.94
1/12/2020	Diaz, Matthew	Transportation	Taxi to the hotel while traveling for case meetings.	66.59
1/13/2020	Bromberg, Brian	Transportation	Taxi from the hotel while traveling for case meetings.	16.59
1/13/2020	Bromberg, Brian	Transportation	Taxi to the hotel while traveling for case meetings.	14.68

EXHIBIT E

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

EXPENSE DETAIL

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Date	Professional	Expense Type	Expense Detail	Amount
1/13/2020	Diaz, Matthew	Transportation	Taxi to the hotel while traveling for case meetings.	30.02
1/15/2020	Broadhead, Gary	Transportation	Rail - Coach/Economy, Gary Broadhead, London Bridge - Cambridge, 01/15/2020 - 01/15/2020. Train ticket to the client site while traveling for case meetings.	33.53
1/15/2020	Broadhead, Gary	Transportation	Rail - Coach/Economy, Gary Broadhead, London Bridge - Cambridge, 01/15/2020 - 01/15/2020. Train ticket for M. Diaz (FTI) to the client site while traveling for case meetings.	33.53
1/15/2020	Broadhead, Gary	Transportation	Rail - Coach/Economy, Gary Broadhead, London Bridge - Cambridge, 01/15/2020 - 01/15/2020. Train ticket for B. Bromberg (FTI) to the client site while traveling for case meetings.	33.53
1/15/2020	Broadhead, Gary	Transportation	Rail - Coach/Economy, Gary Broadhead, London Bridge - Cambridge, 01/15/2020 - 01/15/2020. Train ticket for G. Coutts (Houlihan) to the client site while traveling for case meetings.	33.53
1/15/2020	Broadhead, Gary	Transportation	Rail - Coach/Economy, Gary Broadhead, London Bridge - Cambridge, 01/15/2020 - 01/15/2020. Train ticket for H. Schenk (Houlihan) to the client site while traveling for case meetings.	33.53
1/15/2020	Broadhead, Gary	Transportation	Taxi to the client site while traveling for case meetings.	15.60
1/16/2020	Broadhead, Gary	Transportation	Taxi to the client site while traveling for case meetings.	23.44
1/16/2020	Bromberg, Brian	Transportation	Taxi to the hotel while traveling for case meetings.	17.41
1/16/2020	Tsongidis, Theodoros	Transportation	Rail - Coach/Economy, Theodoros Tsongidis, London - Cambridge, 01/16/2020 - 01/16/2020. Train ticket to the client site while traveling for case meetings.	51.99
1/17/2020	Bradley, Adam	Transportation	Rail - Coach/Economy, Adam Bradley, Cambridge - Preston Park, 01/17/2020 - 01/17/2020. Train ticket to the client site while traveling for case meetings.	58.21
1/17/2020	Bradley, Adam	Transportation	Rail - Coach/Economy, Adam Bradley, Preston Park - Cambridge, 01/17/2020 - 01/17/2020. Train ticket to the client site while traveling for case meetings.	108.76
1/17/2020	Bradley, Adam	Transportation	Taxi from the client site while traveling for case meetings.	15.67
1/17/2020	Bradley, Adam	Transportation	Taxi to the client site while traveling for case meetings.	15.67
1/17/2020	Broadhead, Gary	Transportation	Taxi from the client site while traveling for case meetings.	19.58
1/17/2020	Broadhead, Gary	Transportation	Taxi to the client site while traveling for case meetings.	39.17
1/17/2020	Diaz, Matthew	Transportation	Taxi to the airport in London after attending meetings with the Company.	214.11
1/17/2020	Diaz, Matthew	Transportation	Taxi home from the airport after traveling to London for case meetings.	70.78
1/18/2020	Bromberg, Brian	Transportation	Taxi home from the airport after traveling to London for case meetings.	91.90
1/18/2020	Bromberg, Brian	Transportation	Taxi from the hotel to the airport while traveling home from London.	7.48
1/30/2020	Kurtz, Emma	Transportation	Taxi home from the office after working late on the case.	24.00
Transportation Total				\$ 1,988.38
1/12/2020	Diaz, Matthew	Working Meals	Breakfast at airport while traveling for case meetings.	15.00
1/12/2020	Diaz, Matthew	Working Meals	Dinner while traveling in London for case meetings (2 participants).	40.00
1/13/2020	Bromberg, Brian	Working Meals	Breakfast at airport while traveling for case meetings.	4.99
1/13/2020	Diaz, Matthew	Working Meals	Dinner while traveling in London for case meetings (2 participants).	40.00
1/15/2020	Diaz, Matthew	Working Meals	Dinner while traveling in London for case meetings (5 participants).	100.00
1/16/2020	Bromberg, Brian	Working Meals	Breakfast at hotel in London while traveling for case meetings.	20.00

EXHIBIT E

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

EXPENSE DETAIL

FOR THE PERIOD JANUARY 1, 2020 TO JANUARY 31, 2020

Date	Professional	Expense Type	Expense Detail	Amount
1/16/2020	Tsongidis, Theodoros	Working Meals	Dinner while traveling for case meetings.	13.40
1/17/2020	Bromberg, Brian	Working Meals	Breakfast at hotel in London while traveling for case meetings.	20.00
1/17/2020	Diaz, Matthew	Working Meals	Dinner at London airport while traveling for case meetings.	20.00
1/18/2020	Bromberg, Brian	Working Meals	Breakfast while traveling for case meetings.	7.53
Working Meals Total				\$ 280.92
1/1/2020	Diaz, Matthew	Other	Internet access for case work while traveling.	39.95
1/12/2020	Bromberg, Brian	Other	Internet access for case work while traveling.	16.99
1/12/2020	Diaz, Matthew	Other	Internet access for case work while traveling.	15.65
1/17/2020	Diaz, Matthew	Other	Internet access for case work while traveling.	23.49
Other Total				\$ 96.08
Grand Total				\$ 11,530.84

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.
2. Expenses incurred internationally have been translated to USD using the relevant spot rate.